Submit Your Abstract
Please Note: Submissions with “INCOMPLETE SUBMISSION” status cannot be processed. Your submission is complete when you select “Conclude Submission” at the end of the abstract submission process. On the screen you will see the message, “Your abstract submission has been received.” You will also receive an email with your abstract number and the link to go back and review your submission.
General information subject to change due to circumstances beyond IDWeek’s control.
- Include a concise statement of the research under investigation and its objectives. Define all concepts and abbreviations at first use.
- Describe experimental methods briefly (including relevant numbers of patients and/or microorganisms).
- Describe specific findings and analysis of data. (Promises such as “to be completed” are not acceptable.)
- Include specific conclusions, with supporting statistical analyses when appropriate. (Concluding
statements such as “the results will be discussed” are not acceptable.)
- Do not submit multiple abstracts on overlapping facets of the same project unless each abstract has important, novel information and clearly stands on its own. Repetitive abstracts will be rejected.
- Abstracts must not be submitted if previously presented at a national or international meeting such as, but not limited to, IDSA, SHEA, ASTMH, ICAAC, ASM, CROI, ASM Microbe or ECCMID. Abstracts that have been previously presented, but include updated information with significant new implications will be considered.
- Resolve any issues relating to patent matters before submitting the abstract.
- Authors do not have to be members of one of the sponsoring societies to submit an abstract.
- Obtain approval in advance from all co-authors before placing their names on the abstract. Submission of an abstract denotes that co-authors as well as authors have read the abstract, take responsibility for its content, and approve that their names appear on the abstract. Failure to obtain approval from all authors will result in immediate rejection of the abstract.
- All authors must agree to the IDWeek embargo and copyright policy.
- All authors must provide disclosures of potential conflicts of interest and complete an attestation form. List any financial interests, assistance, or relationships with companies, supporters, or commercial products that are related to the research (for example, research support, grants, sponsors, stockholder, etc.). A response to this request must be provided for each author or author group before the abstract can be peer reviewed.
- Adding or removing authors after the submission deadline is not permitted.
Abstract disposition notices will be sent on Thursday, July 9 via e-mail to presenting authors only. Late breaker abstract disposition notices will be sent on or before Wednesday, September 16 via e-mail to presenting authors only. Abstract dispositions will not be provided over the telephone. It is the responsibility of the presenting author to notify and ensure that all co-authors are informed that the abstract has either been accepted or rejected, and to disseminate the presentation scheduling information. If your abstract is accepted, you will receive guidelines for preparing poster or oral presentations. Please note that due to the large number of abstracts, IDWeek will not consider special scheduling requests for poster or oral presentations.
If the presenting author does not receive their notification by 11:59 p.m. on July 9, 2020 (September 16 for late breaker abstracts), please send an email to email@example.com. Include the abstract ID number, the name of the presenting author, and the title of the abstract in the request. Notifications will not be provided over the phone.